Company intelligence / Profile preview

Triangle Pharmaceuticals, Inc.

Durham, North Carolina, United Statessec.gov ↗

Ownership: Private
Development stage: NDA

Overview

Triangle Pharmaceuticals developed Coviracil (emtricitabine, FTC), which was near FDA approval at the time of acquisition by Gilead. Emtricitabine was later approved by the FDA in July 2003 for the treatment of HIV infection in combination with other antiretroviral agents.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

emtricitabine

NDA

Indications: HIV

2 more assets in the full pipeline.

Request access →

Partnerships

Terrapin Technologies Inc.Warner-Lambert Co.

Beyond the preview

Go deeper on Triangle Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Triangle Pharmaceuticals, Inc..

Explore the full profile